Novel Topical Found Effective for Psoriasis in 52-Week Study

Benefits of treatment with tapinarof 1% were seen even with intermittent use in the extension trial.

Related Keywords

Yuriage ,Rhôalpes ,France ,Paris ,France General ,Michigan ,United States ,Washington ,Marius Anton Ionescu ,Adam Friedman ,Eli Lilly ,Bristol Myers Squibb ,Glaxosmithkline ,European Academy Of Dermatology ,Amgen ,Drug Administration ,Novartis ,Pfizer ,Henry Ford Health System ,Dermavant Sciences ,Johnson ,Valeant Pharmaceuticals ,Health Sciences ,European Academy ,Linda Stein Gold ,Physician Global Assessment ,George Washington School ,Anton Ionescu ,Saint Louis ,Leo Pharma Ortho Dermatologic ,Psoriasis ,Clinical Research ,Clinical Trials ,Linical Studies ,Alzheimers Disease ,Lzheimer Disease ,Amyloid Plaque ,Contact Dermatitis ,Dermatitis ,Topical Corticosteroids ,Atopic Dermatitis ,Europe ,European ,Facial ,Irritants ,Ear Gas Cs ,Riot Control Agents ,Achrymators ,Hloroacetophenone Cn ,Rritant Chloropicrin Ps ,Romobenzenecyanide Ca ,Hloroform Cnc ,N Carbon Tetrachlor ,